Life Science Invest Fund

Prostatype Genomics AB press releases Prostatype Genomics AB has issued two interesting press releases this week. The first is regarding submission of application for Medicare reimbursement which confirms to us, that Prostatype Genomics AB so far is living up to the ambitious time schedule laid out regarding laying the foundation for entering the US market on a bigger scale. The second refers to an interesting study by IHE showing that use of the company's gene test could save SEK 600 million each year in Sweden alone showcasing the enormous potential savings on health economics around the world. At LSIF, we look forward to the continiuos news in the coming month. #lsif #lifescienceinvestfund #prostatype #prostatecancer

Life Science Invest Fund (LSIF) increases investment in Acarix Acarix has announced a subscription rate of 96.2% for the TO3 warrant. Acarix will receive approximately SEK 22.6 million before issuance costs which we estimate will bring the company well into H2 2025. At LSIF we are pleased to see this strong support from the shareholders. LSIF is by far the largest subscriber in this round, and LSIF also participates in the guarantor consortium to secure an total subscription rate of 100%. For LSIF, this is our third financing round in Acarix emphazing our long term commitment to our portfolio companies. #lifescienceinvestfund #lsif #cadscor

Lipidor AB advances in Phase III This evening Lipidor AB announced that the first patient has now been enrolled in the Phase III clinical study with AKP02G2. With this announcement yet another milestone is being met on time showing that CEO Ola Holmlund and his team are delivering as scheduled. We look forward to getting to know when more centers becomes active, and we still anticipate, that the end result will be delivered in Q1 2025. #lifescienceinvestfund #lsif #AKP02G2 #akvano #psoriasis #enstilar

LSIF invests in PMD Solutions LSIF has as a result of the rights issue in PMD Solutions invested SEK 6,2 mio. in the company. LSIF will become the 3rd largest shareowner in PMD Solutions, and we look forward to follow PMD Solutions grow and deliver on the newly revised financial guidance. With this rights issue PMD Solutions has secured the funding needed until becoming cash flow positive, so no more funding activities are to be expected, and the management can now focus entirely on achieving its operational goals. At LSIF, we look forward to work with PMD Solutions. #lsif #lifescienceinvestfund #pmd #MakingEveryBreathCount #virtualwards #RespiratoryFailure

LSIF becomes a major shareholder in Prostatype Genomics AB Yesterday, Prostatype Genomics AB announced the good result of the rights issue carried out to finance the ongoing study in the US to be completed shortly and for commercial activities until the company is expected to receive approval from Medicare towards the end of this year. As the lead guarantor in the rights issue, LSIF has become a major shareholder in Prostatype Genomics AB, which is fully aligned with our intention as guarantor, and we are exited to be on board for the journey ahead of the company. We intend to provide stability and staying on as a major shareholder in close contact with the management. We also want to take the opportunity to thank Gemstone Capital A/S for a well arranged financing for Prostatype Genomics AB #lsif #lifescienceinvestfund #gemstonecapital #prostatecancer

Acarix CEO buys shares We are pleased to note yesterdays press release from Acarix regarding CEO Aamir Mahmood purchasing 2,261,753 shares in the company in the open market. It is always significant and affirming, when management or board members choses to invest their own money in the company, and we wellcome this strong signal. Aamir Mahmood now owns 5,404,567 shares. #lsif #lifescienceinvestfund #cadscor

Acarix secures TO3 subscription LSIF is pleased to announce, that in addition to being the largest subscriber in the current TO3 financing round, we further support Acarix by participating as a guarantor in the consortium set up to ensure a 100% subscription of the TO3 warrants. We believe that Acarix, with the certainty of full utilization of TO3, will be financially secured in a period where it is important that the management can focus on gearing the organization to ramp up sales. #lsif #lifescienceinvestfund #cadscor

Lipidor AB is on right track Today Lipidor AB announced its Q2 results and at LSIF we are pleased to see that Lipidor AB is on the right track both financially, with good cost control and equally importantly in terms of progress in the Phase III study. We look forward to hopefully getting updated information as the study progresses, and it will be interesting to see if the company can continue to deliver on the very tight timeline it has set for the study. If successful, AKP02 will mean so much to so many psoriasis patients. #lsif #lifescienceinvestfund #psoriasis #akvano #akp01 #akp02

LSIF to further invest in Acarix Although we find the revenue in the Q2 report to be below our expectations, we also see many positive developments initiated by the current CEO Aamir Mahmood, and we remain absolutely confident in the vast potential of the CADScor system. We have thus decided to once more support Acarix by subscribing on our 16,7 mio. TO3 warrants investing between 4,2 mio SEK and 8,4 mio. SEK depending on the final exercise price. On top of this, entities closely affiliated to us will invest between 2 and 4 mio SEK. #lsif #lifescienceinvestfund #cadscor #to3

PMD Solutions releases preliminary P&L results ahead of Q2 Interim Report Today, Myles Murray, CEO of PMD Solutions announced that consolidated net sales increased by 30.9% in Q2, which is in line with expectations in the newly significantly increased financial target for 2024 - 2026. Operating expenses increased more than we at LSIF expected due to one time costs related to the restructuring of the acquired US operation. For LSIF the most important message was, that PMD Solutions maintains, that the company will be cash flow positive by the end of 2024. LSIF is a lead guarantor in the upcoming rights issue Aug. 19th to Sept. 2nd. With the revised financial goals in June and todays press release, LSIF remain confident in PMDS and look forward to becoming a major shareholder. #lsif #lifescienceinvestfund #RespiraSense #MakingEveryBreathCount #virtualwards